Phathom Pharmaceuticals to Hold Conference Call for Q3 2025 Financial Results and Business Update on October 30

Phathom Pharmaceuticals will host a conference call on October 30, 2025, to discuss Q3 financial results and business updates.

Quiver AI Summary

Phathom Pharmaceuticals, Inc. has announced that it will host a live webcast on Thursday, October 30, 2025, at 8:00 am EDT to discuss its third quarter 2025 financial results and provide a business update. The webcast will be accessible through the Events & Presentations section of the Phathom website, and a recording will be available for 90 days after the event. Phathom is focused on developing innovative treatments for gastrointestinal diseases and has exclusive rights to market vonoprazan, a potassium-competitive acid blocker, in the U.S., Europe, and Canada. The company currently markets vonoprazan as VOQUEZNA® for various conditions in adults. More details can be found on their website and through their media and investor contacts.

Potential Positives

Phathom Pharmaceuticals is set to report its third quarter 2025 financial results, which could indicate positive financial performance and growth potential.
The company is actively engaging with investors through a live conference call, demonstrating transparency and commitment to communication.
Phathom has in-licensed exclusive rights to vonoprazan, a first-in-class treatment for gastrointestinal diseases, showcasing its focus on innovative therapeutics.
Phathom currently markets vonoprazan in the U.S., expanding its product portfolio and addressing significant healthcare needs related to gastrointestinal disorders.

Potential Negatives

Announcement of the conference call does not reveal any significant new information regarding financial performance or business outlook, which may raise concerns among investors about transparency.
Phathom Pharmaceuticals is still heavily reliant on a single product, vonoprazan, for its revenue, which poses risks if market conditions or competitive dynamics change adversely.
The timing of the conference call on October 30, 2025, suggests that results may not align with market expectations, creating potential volatility in share price after the announcement.

FAQ

When will Phathom Pharmaceuticals host its conference call?

Phathom Pharmaceuticals will host its conference call on Thursday, October 30, 2025, at 8:00 am EDT.

How can I access the live webcast for the conference call?

The live webcast can be accessed on the Events & Presentations section of the Phathom website.

What financial results will Phathom Pharmaceuticals report?

Phathom Pharmaceuticals will report its third quarter 2025 financial results during the conference call.

Is there a recording available after the live conference call?

Yes, a recording of the conference call will be available for 90 days following the event.

What focus does Phathom Pharmaceuticals have in their business?

Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PHAT Insider Trading Activity

$PHAT insiders have traded $PHAT stock on the open market 10 times in the past 6 months. Of those trades, 8 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $PHAT stock by insiders over the last 6 months:

JAMES N TOPPER has made 6 purchases buying 59,403 shares for an estimated $191,988 and 0 sales.
ASIT PARIKH has made 2 purchases buying 10,000 shares for an estimated $24,984 and 0 sales.
ROBERT CHARLES BREEDLOVE (Principal Accounting Officer) has made 0 purchases and 2 sales selling 2,153 shares for an estimated $19,725.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PHAT Hedge Fund Activity

We have seen 60 institutional investors add shares of $PHAT stock to their portfolio, and 68 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JENNISON ASSOCIATES LLC removed 7,042,325 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $67,535,896
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 2,357,210 shares (+23.3%) to their portfolio in Q2 2025, for an estimated $22,605,643
MILLENNIUM MANAGEMENT LLC added 1,727,134 shares (+330.0%) to their portfolio in Q2 2025, for an estimated $16,563,215
TANG CAPITAL MANAGEMENT LLC removed 1,200,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,508,000
MORGAN STANLEY removed 976,104 shares (-86.3%) from their portfolio in Q2 2025, for an estimated $9,360,837
CATALIO CAPITAL MANAGEMENT, LP added 672,290 shares (+inf%) to their portfolio in Q2 2025, for an estimated $6,447,261
683 CAPITAL MANAGEMENT, LLC added 660,000 shares (+45.7%) to their portfolio in Q2 2025, for an estimated $6,329,400

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$PHAT Analyst Ratings

Wall Street analysts have issued reports on $PHAT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Craig-Hallum issued a "Buy" rating on 06/09/2025
HC Wainwright & Co. issued a "Buy" rating on 06/09/2025
Needham issued a "Buy" rating on 06/06/2025
Guggenheim issued a "Buy" rating on 05/02/2025

To track analyst ratings and price targets for $PHAT, check out Quiver Quantitative's $PHAT forecast page.

$PHAT Price Targets

Multiple analysts have issued price targets for $PHAT recently. We have seen 5 analysts offer price targets for $PHAT in the last 6 months, with a median target of $17.0.

Here are some recent targets:

Chase Knickerbocker from Craig-Hallum set a target price of $17.0 on 06/09/2025
Matthew Caufield from HC Wainwright & Co. set a target price of $20.0 on 06/09/2025
Joseph Stringer from Needham set a target price of $28.0 on 06/06/2025
Paul Choi from Goldman Sachs set a target price of $5.0 on 05/02/2025
Yatin Suneja from Guggenheim set a target price of $12.0 on 05/02/2025

Full Release

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT

FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations . A recording will be available for 90 days following the conclusion of the call.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA ^® TRIPLE PAK ^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ^® DUAL PAK ^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X .

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
[email protected]

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
[email protected]

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.